Efforts Continue to Optimize Immunotherapy in Gastric Cancer – OncLive
|
Efforts Continue to Optimize Immunotherapy in Gastric Cancer
OncLive The treatment of gastric cancer with immunotherapy continues to be an exciting area of investigation, particularly with the PD-1 inhibitors pembrolizumab (Keytruda) and nivolumab (Opdivo). In the phase III ONO-4538-12 trial, treatment in the third-line … |
